Display options
Cite
Cecchini S, Sarti D, Ricci S, et al. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World J Clin Oncol. 2015;6(4):57-63doi: 10.5306/wjco.v6.i4.57.
Cecchini, S., Sarti, D., Ricci, S., Vergini, L. D., Sallei, M., Serresi, S., Ricotti, G., Mulazzani, L., Lattanzio, F., & Fiorentini, G. (2015). Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World journal of clinical oncology, 6(4), 57-63. https://doi.org/10.5306/wjco.v6.i4.57
Cecchini, Sara, et al. "Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma." World journal of clinical oncology vol. 6,4 (2015): 57-63. doi: https://doi.org/10.5306/wjco.v6.i4.57
Cecchini S, Sarti D, Ricci S, Vergini LD, Sallei M, Serresi S, Ricotti G, Mulazzani L, Lattanzio F, Fiorentini G. Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma. World J Clin Oncol. 2015 Aug 10;6(4):57-63. doi: 10.5306/wjco.v6.i4.57. PMID: 26266102; PMCID: PMC4530379.
Copy Download .nbib Format: NLM
Share it on

World J Clin Oncol. 2015 Aug 10;6(4):57-63. doi: 10.5306/wjco.v6.i4.57.

Isolated limb infusion chemotherapy with or without hemofiltration for recurrent limb melanoma.

World journal of clinical oncology

Sara Cecchini, Donatella Sarti, Stefano Ricci, Ludovico Delle Vergini, Manuela Sallei, Stefano Serresi, Giuseppe Ricotti, Luca Mulazzani, Fabrizia Lattanzio, Giammaria Fiorentini

Affiliations

  1. Sara Cecchini, Stefano Ricci, Ludovico Delle Vergini, Manuela Sallei, Department of Vascular and Interventional Radiology, INRCA Hospital- IRCCS, 60127 Ancona, Italy.

PMID: 26266102 PMCID: PMC4530379 DOI: 10.5306/wjco.v6.i4.57

Abstract

AIM: To better define the efficacy and the safety of intra-arterial infusion performed with or without hemofiltration for recurrent limb melanoma.

METHODS: Patients with the following characteristics were included in the study: recurrent limb melanoma not indicated for surgical resection, measurable disease in the extremity, > 18 years, performances status (Eastern Cooperative Oncology Group ) was 0-1 and life expectancy of at least 6 mo. Twenty nine consecutive patients were enrolled in the study. Patients underwent fluoroscopic placement of angiographic arterial and venous catheters to infuse the drug in the artery [isolated limb infusion (ILI)], and to stop the out flow (venous). Melphalan was rapidly infused into the isolated limb via the arterial catheter after the inflation of venous balloon catheter. Then the circulation of the limb was completely blocked with a pneumatic cuff at the root of the limb. Haemofiltration (HF) was available only in the main center, and was performed with an extracorporeal perfusion system, in order to reduce high systemic toxic peaks of drug.

RESULTS: Thirty seven ILI were done in 29 cases (31 ILI-HF and 6 ILI) between 2001 and 2014 at Ancona and Pesaro Hospitals, Italy. Clinical outcomes were monitored 30 d after treatment. Eleven patients (38%) received infusion of melphalan alone, 7 (24%) melphalan associated to mitomicin C and 7 (24%) melphalan associated to cisplatin, the remaining 4 were treated with cisplatin, melphalan and epirubicin or cisplatin and mitomicin C. The overall response rate was 66%, in particular, 3 patients (10%) were complete responders and 16 (56%) were partial responders; whereas 7 patients (24%) had stable disease, and 3 (10%) showed progressive disease. Limb toxicity was assessed adopting Wieberdink scale, with evidence of 90% of low grade (I and II) toxicity.

CONCLUSION: ILI-HF and ILI are effective and safe treatments for recurrent non-resectable limb melanoma. They present evidence of favorable clinical benefit and is effective in delaying progression.

Keywords: Hemofiltration; Intra-arterial infusion; Melphalan; Metastatic melanoma

References

  1. Semin Cutan Med Surg. 2012 Mar;31(1):45-9 - PubMed
  2. Cancer. 2003 Oct 1;98(7):1483-90 - PubMed
  3. J Clin Pharmacol. 1998 Oct;38(10):936-44 - PubMed
  4. J Surg Oncol. 2014 Jun;109(8):780-5 - PubMed
  5. Am J Surg. 2002 Jan;183(1):28-36 - PubMed
  6. Melanoma Res. 2003 Feb;13(1):51-8 - PubMed
  7. Curr Top Med Chem. 2012;12(1):53-60 - PubMed
  8. Int J Hyperthermia. 2008 May;24(3):227-37 - PubMed
  9. Br J Cancer. 2001 Jul 20;85(2):157-65 - PubMed
  10. J Clin Oncol. 2014 Jul 20;32(21):2248-54 - PubMed
  11. Ann Surg Oncol. 2008 Nov;15(11):3003-13 - PubMed
  12. Ann Surg Oncol. 2007 Jan;14(1):230-8 - PubMed
  13. Cancer. 2009 May 1;115(9):1932-40 - PubMed
  14. Arch Surg. 1997 Aug;132(8):903-7 - PubMed
  15. Semin Surg Oncol. 1998 Apr-May;14(3):238-47 - PubMed
  16. Ann Surg Oncol. 2002 Mar;9(2):127-36 - PubMed
  17. Int J Artif Organs. 2004 May;27(5):414-9 - PubMed
  18. J Am Coll Surg. 2009 May;208(5):706-15; discussion 715-7 - PubMed
  19. N Engl J Med. 2013 Apr 4;368(14 ):1365-6 - PubMed
  20. Eur J Cancer. 2010 Jan;46(2):270-83 - PubMed
  21. Cancer Manag Res. 2013 Aug 20;5:243-9 - PubMed
  22. Eur J Cancer Clin Oncol. 1982 Oct;18(10):905-10 - PubMed
  23. Tumori. 2006 Sep-Oct;92(5):402-6 - PubMed
  24. J Surg Oncol. 2009 Aug 1;100(2):169-77 - PubMed
  25. Support Care Cancer. 2006 Jan;14(1):30-7 - PubMed
  26. Br J Surg. 1996 Oct;83(10):1319-28 - PubMed
  27. J Surg Oncol. 2005 Aug 1;91(2):107-11 - PubMed

Publication Types